Payment overview · 2025
General Payments
We did not find matching Open Payments records for this doctor in the selected program year.
Healthcare provider profile · identity verified
Family Practice · METHUEN, MA · NPI 1073889226
Verified facts
We did not find matching Open Payments records for this doctor in 2025.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
We did not find matching Open Payments records for this doctor in the selected program year.
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Analysis 1 · Payment-linked products
No payment-linked product analysis is available because no matching General Payment records were found for the selected year.
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
There is no payer-company set available for this comparison.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 77 |
| Lisinopril | Lisinopril | 233 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 72 |
| Ezetimibe | Ezetimibe | 134 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 117 | 30 |
| Omeprazole | Omeprazole | 110 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 35 |
| Metformin Hcl | Metformin Hcl | 102 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 22 |
| Trazodone Hcl | Trazodone Hcl | 72 | 21 |
| Simvastatin | Simvastatin | 65 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 22 |
| Metformin Hcl Er | Metformin Hcl | 60 | 18 |
| Rybelsus | Semaglutide | 59 | 14 |
| Losartan Potassium | Losartan Potassium | 55 | 18 |
| Ozempic | Semaglutide | 54 | suppressed |
| Jardiance | Empagliflozin | 48 | 13 |
| Atenolol | Atenolol | 46 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 14 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Furosemide | Furosemide | 45 | 13 |
| Gabapentin | Gabapentin | 44 | 12 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | 13 |
| Allopurinol | Allopurinol | 42 | 12 |
| Lorazepam | Lorazepam | 42 | 11 |
| Eliquis | Apixaban | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Carvedilol | Carvedilol | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 12 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Prednisone | Prednisone | 24 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | 11 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | — | — | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error